Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MXCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMXCTMaxCyte$2.30-0.4%$2.53$2.10▼$5.26$245.60M1.38600,810 shs1.15 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMXCTMaxCyte0.00%+5.02%-17.56%-31.14%-50.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMXCTMaxCyte2.5648 of 5 stars3.52.00.00.02.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMXCTMaxCyte 3.00Buy$7.50226.09% UpsideCurrent Analyst Ratings BreakdownLatest CREO, MXCT, EKF, and IUG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025MXCTMaxCyteBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$6.003/12/2025MXCTMaxCyteStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $9.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMXCTMaxCyte$37.68M6.49N/AN/A$2.23 per share1.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMXCTMaxCyte-$37.92M-$0.40N/AN/AN/A-78.36%-16.00%-13.93%8/5/2025 (Estimated)Latest CREO, MXCT, EKF, and IUG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025MXCTMaxCyte-$0.10-$0.10N/A-$0.10$9.05 million$10.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMXCTMaxCyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMXCTMaxCyteN/A9.819.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMXCTMaxCyte68.81%Insider OwnershipCompanyInsider OwnershipMXCTMaxCyte3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMXCTMaxCyte80106.32 million102.67 millionOptionableCREO, MXCT, EKF, and IUG HeadlinesRecent News About These CompaniesMillennium Management LLC Sells 1,451,994 Shares of MaxCyte, Inc. (NASDAQ:MXCT)May 26, 2025 | marketbeat.comMaxCyte, Inc. (NASDAQ:MXCT) Shares Sold by Lazard Asset Management LLCMay 23, 2025 | marketbeat.comDimensional Fund Advisors LP Has $5.95 Million Stock Holdings in MaxCyte, Inc. (NASDAQ:MXCT)May 13, 2025 | marketbeat.comWilliam Blair Predicts MaxCyte's Q2 Earnings (NASDAQ:MXCT)May 13, 2025 | marketbeat.comMaxCyte, Inc. (MXCT) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comAxa S.A. Makes New $4.11 Million Investment in MaxCyte, Inc. (NASDAQ:MXCT)May 10, 2025 | marketbeat.comMaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comMaxCyte, Inc.: MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 GuidanceMay 7, 2025 | finanznachrichten.deMaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 GuidanceMay 7, 2025 | globenewswire.comCadian Capital Management LP Buys 1,155,476 Shares of MaxCyte, Inc. (NASDAQ:MXCT)May 7, 2025 | marketbeat.comMaxCyte Expands Stock Capital with New Share IssuanceMay 2, 2025 | tipranks.comMaxCyte (MXCT) Expected to Announce Quarterly Earnings on WednesdayMay 2, 2025 | marketbeat.comRenaissance Technologies LLC Has $1.17 Million Stock Position in MaxCyte, Inc. (NASDAQ:MXCT)May 2, 2025 | marketbeat.comBlackRock Adjusts Stake in MaxCyte, Inc.April 22, 2025 | tipranks.comMaxCyte intends to delist from London's AIM to enhance liquidityApril 15, 2025 | lse.co.ukMaxCyte to Delist from AIM, Focus on NasdaqApril 15, 2025 | tipranks.comMaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025April 10, 2025 | globenewswire.comMaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025April 10, 2025 | globenewswire.comWith 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big gunsApril 8, 2025 | uk.finance.yahoo.comDown -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)April 8, 2025 | zacks.comDown -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a TurnaroundApril 7, 2025 | zacks.comMedia Sentiment Over TimeCREO, MXCT, EKF, and IUG Company DescriptionsMaxCyte NASDAQ:MXCT$2.30 -0.01 (-0.43%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$2.38 +0.08 (+3.48%) As of 05/30/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
